$PTI they sound very bullish with upcoming results ๐Ÿ‘‡๐Ÿ‘€ โ€œDue to this strong demand for options and additional trials from the patient and medical community, we're pleased to announce that we now expect top-line data from the Phase 2 study later this quarter." The 28-day Phase 2 study follows the positive results of the 14-day Phase 1 clinical studies of PTI's proprietary doublet and triplet combinations in F508del homozygous patients, including those predisposed to rapid pulmonary decline based on their bacterial colonization status. The previous studies demonstrated a favorable safety and tolerability profile for the combinations, as well as a statistically significant improvement in ppFEV1 and sweat chloride concentration that was superior to the available dual CFTR modulator standard of care.
  • 7
  • 6